In this episode of Financial Modeler’s Corner, host Paul Barnhurst (aka the FP&A Guy) sits down with Frank David, an expert at the intersection of corporate strategy, clinical medicine, and biotech research. They discuss the unique challenges of financial modeling in the biopharma industry, the importance of understanding patient populations, and how drug development strategy influences financial decision-making.
Frank David is the Founder and Managing Director of Pharmagellan, a consulting firm specializing in biotech financial modeling and valuation. With a background as a physician scientist, Frank has extensive experience advising biopharma teams and investors. He also teaches at Tufts University and is the lead author of The Pharmagellan Guide to Biotech Forecasting and Valuation and The Pharmagellan Guide to Analyzing Biotech Clinical Trials.
Expect to Learn:
Here are a few quotes from the episode:
This episode explored the complexities of biotech financial modeling. Frank shared why traditional financial modeling approaches don’t always work in the biotech industry and how strategic decision-making relies heavily on understanding patient needs, regulatory pathways, and risk assessment.
Follow Frank:
Follow Paul:
Follow Financial Modeler's Corner
Sign up for the Advanced Financial Modeler Accreditation Today
Published on 9 months, 3 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate